Abstract: Aim: We have previously reported the mid-term efficacy and safety of tacrolimus (Tac)-based immunosuppressive therapy in such patients, and herein, we aimed to determine their long-term outcomes (over 10 years).
Methods: We retrospectively evaluate the data of 13 consecutive patients with biopsy-proven long-standing LN who underwent a long-term Tac-based treatment regimen. Tac was administered once daily at a dose of 3 mg as reinduction or maintenance treatment. Treatment outcomes were defined using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), urinary protein/creatinine ratio (Up/cr), serum creatinine, estimated glomerular filtration rate (eGFR) and serological lupus markers (complement C3, complement hemolytic activity [CH 50], and anti-dsDNA antibody titre), and the concomitantly administered prednisolone (PDN) dose. Data on clinical parameters and serological lupus activity were collected annually from each patient throughout the study period.
Results: The patients' baseline characteristics at the treatment initiation were as follows: mean age, 18 years; Up/cr, 0.63 ± 0.69; serum C3 level, 57.2 ± 22.4 mg/dL (normal range, 79-152 mg/dL); CH50, 27.9 ± 15.7 U/mL (normal range, 23.0-46.0 U/mL); serum anti-dsDNA antibody titre, 111.7 ± 123.4 IU/mL (normal range, <12.0 IU/mL); serum creatinine, 0.60 ± 0.19 mg/dL; eGFR, 115.6 ± 21.3 mL/min and SLEDAI, 13 ± 8.1. Despite the gradual tapering of the concomitantly administered PDN dose from 18.7 ± 13.5 mg/day at baseline to 3.5 ± 2.8 mg/day at 10 years (p = .002), a marked improvement in the outcomes, compared with the baseline values, was observed within a year. Additionally, these favourable changes persisted throughout study period in most patients. Compared with the baseline values, the following measures confirmed sustained outcome improvements after a 10-year treatment: SLEDAI, 1.7 ± 2.0; serum C3 level, 83.8 ± 16.1 mg/dL; CH50, 45.6 ± 10.9 U/mL (all p < .01) and Up/cr, 0.16 ± 0.18 and serum anti-dsDNA antibody titre, 25.8 ± 28.8 IU/mL (both p < .05). Serum creatinine level and eGFR remained within the normal range in all study participants except for one patient who experienced several flare-ups. No serious adverse effects were observed.
Conclusion: Our results suggest that long-term Tac-based immunosuppressive treatment as maintenance therapy is beneficial and has low cytotoxicity. Therefore, it represents an attractive option for the treatment of selected patients with paediatric-onset LN in a real-world setting.
(© 2024 Asian Pacific Society of Nephrology.)
References: Anders HJ, Saxena R, Zhao M, Parodis I, Salmon JE, Mahan C. Lupus nephritis. Nat Rev Dis Primers. 2020;6:7.
Lichtnekert J, Anders HJ, Lech M. Lupus nephritis: current perspectives and moving forward. J Inflamm Res. 2022;15:6533‐6552.
Fanouriakis A, Kostopoulou M, Cheema K, et al. 2019 update of the joint European league against rheumatism and European renal association‐European dialysis and transplantation association (EULAR/ERA‐EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis. 2020;79:713‐723.
Aggarwal A, Srivastava P. Childhood onset systemic lupus erythematosus: how is it different from adult SLE? Int J Rheum Dis. 2015;18:182‐191.
Mok CC, Yap DYH, Navarra SV, et al. Overview of lupus nephritis management guidelines and perspective from Asia. Nephrology. 2014;19:11‐20.
Yap DYH, Chan TM. Lupus nephritis in Asia: clinical futures and management. Kidney Dis. 2015;1:100‐109.
Yap DYH, Ma MKM, Mok MMY, Kwan LPY, Chan GCW, Chan TM. Long‐term data on tacrolimus in lupus nephritis. Rheumatology. 2014;53:2232‐2237.
Karasawa K, Uchida K, Kodama M, Motoyama T, Nitta K. Long‐term effects of tacrolimus for maintenance therapy of lupus nephritis: a 5‐year retrospective study at a single center. Rheumatol Int. 2018;38:2271‐2277.
Tanaka H, Watanabe S, Aizawa‐Yashiro T, et al. Long‐term tacrolimus‐based immunosuppressive treatment for young patients with lupus nephritis: a prospective study in daily clinical practice. Nephron Clin Pract. 2012;121:c165‐c173.
Hannah J, Casian A, D'Cruz D. Tacrolimus use in lupus nephritis: a systemic review and meta‐analysis. Autoimmun Rev. 2016;15:93‐101.
Ikezumi Y, Kanno K, Koike H, et al. FK506 ameliorate proteinuria and glomerular lesions induced by anti‐thy 1.1 monoclonal antibody 1‐22‐3. Kidney Int. 2001;61:1339‐1350.
Tanaka H, Tsuruga K, Watanabe S, Aizawa‐Yashiro T, Imaizumi T. Treatment of young patients with lupus nephritis with calcineurin inhibitors. World J Nephrol. 2012;1:177‐183.
Tanaka H, Joh K, Imaizumi T. Treatment of pediatric‐onset lupus nephritis: a proposal of optimal therapy. Clin Exp Nephrol. 2017;21:755‐763.
Takeuchi T, Wakasugi N, Uno S, Makino H. Long‐term safety and effectiveness of tacrolimus in patients with lupus nephritis: 5‐year interim postmarketing surveillance study in Japan (TRUST). J Rheumatol. 2021;48:74‐81.
Takeuchi T, Wakasugi N, Hashida T, Uno S, Makino H. Long‐term safety and effectiveness of tacrolimus in patients with lupus nephritis in Japan: 10‐year analysis of the real‐world TRUST study. J Rheumatol. 2024;51:613–621.
Tanaka H, Aizawa T, Watanabe S, Oki E, Tsuruga K, Imaizumi T. Efficacy of mizoribine‐tacrolimus‐based induction therapy for pediatric lupus nephritis. Lupus. 2014;23:813‐818.
Uemura O, Nagai T, Ishikura K, et al. Creatinine‐based equation to estimate the glomerular filtration rate in Japanese children and adolescents with chronic kidney disease. Clin Exp Nephrol. 2014;18:626‐633.
Tanaka H. Long‐term outcome of tacrolimus monotherapy in a patient with lupus nephritis: a 12‐year observation. Lupus. 2023;32:1138‐1140.
Tsugawa K, Tanaka H, Kudo M, Nakahata T, Ito E. Renal artery thrombosis in a pediatric case of systemic lupus erythematosus without antiphospholipid antibodies. Pediatr Nephrol. 2005;20:1648‐1650.
Tse KC, Lam MF, Tang SCW, Tang CSO, Chan TM. A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibitor or blockade. Lupus. 2007;16:46‐51.
Ho LY, Ying SKY, Leung MC, To CH, Ng WL. Long‐term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis. 2020;79:1070‐1076.
Yap DYH, Li PH, Tang C, et al. Long‐term results of triple immunosuppression with tacrolimus added mycophenolate and corticosteroids in the treatment of lupus nephritis. Kidney Int Rep. 2022;7:516‐525.
Processing Request
No Comments.